OUTSTANDING RESULT FOR AFFIRIS ALZHEIMER'S VACCINE IN THE LATEST THOMSON "THE ONES TO WATCH" RANKING
Vienna, 19 December 2007. The Alzheimer's vaccine AD01 from AFFIRIS GmbH has been listed in first place in an analysis conducted by the international ranking agency Thomson Scientific into the prospects for success of current clinical trials. The ranking assesses the prospects of clinical trials around the world, regardless of the disease in question. The Austrian company's Alzheimer's vaccine was described as one of the "most promising drugs entering Phase I trials". The world-leading information provider for science and research published its findings in its latest quarterly report on the worldwide development of medicines. Special mention was given to AFFIRIS GmbH's innovative platform technology AFFITOME, which also provides the company with a basis for developing other products.
AFFIRIS GmbH, based in Vienna, Austria, today announced that Thomson Scientific has identified the company's Alzheimer's vaccine AD01 as one of the most interesting developments worldwide in clinical phase I. Thomson Scientific, based in New York, is the most highly respected provider of information on science and research. It publishes the Citation Index, a reference for weighting scientific journals, and therefore has significant influence on the career opportunities of publishing scientists.
In the quarterly report which has just been released for July - September 2007, "The Ones to Watch - Thomson Scientific's review of phase changes in the pharmaceutical pipeline", special praise is reserved for AFFIRIS' innovative peptide-based Alzheimer's vaccine AD01. The advantage of this technology is that it overcomes the problem of a potential autoimmune reaction to the vaccine. Dr. Walter Schmidt, CEO of AFFIRIS GmbH, comments:
"Autoimmune reactions are a major challenge in the development of Alzheimer's vaccines. The root of the problem is that the disease is caused by detached parts of one of the body's own proteins known as beta-amyloids. The issue of autoimmune reactions has led to other companies failing in their attempts to develop successful vaccines against Alzheimer's because their vaccines have not only attacked the beta-amyloid but also the body'sown protein APP, which is essential for healthy brain cell function."
The patented AFFITOME technology from AFFIRIS GmbH has enabled the company to manufacture a vaccine to target the relevant structures of human rogue proteins. Individual vaccine candidates are known as AFFITOPE, while the entire number of all possible candidates is referred to as the AFFITOME. The Alzheimer's vaccine AD01, for example, can be used to target a specific structure of the beta-amyloid. The healthy, intact protein APP is not attacked because it does not exhibit this structure.
Initial results from the ongoing AD01 trial are due to be published in the second half of 2008. By then, AFFIRIS will already have begun trialling a second Alzheimer's vaccine, AD02, which also uses the beneficial AFFITOME technology. The company's largest investor, MIG-Fonds, is also impressed with the structure of the company's development pipeline. Michael Motschmann, Senior Fund Manager at MIG-Fonds explains: "AFFIRIS is cleverly utilizing AFFITOME technology to develop treatments for diseases that urgently require a medical solution and also offer attractive market potential. Needless to say, with 22 million sufferers predicted for 2025 and no effective treatment, Alzheimer's is one such disease. AFFIRIS has other projects in the pipeline targeted at developing medicines for the treatment of atherosclerosis. As investors, we welcome both the huge market potential of this strategy and also the diversification of risk."
About AFFiRiS GmbH (as at December 2007): AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other serious diseases. The company has established its AFFITOME platform technologies. It employs 30 highly qualified members of staff on 600 sqm of rented laboratory facilities at the Campus Vienna Biocenter (www.affiris.com). AFFITOPE and AFFITOME are registered trademarks of AFFIRIS GmbH.
About MIG-Fonds:
The participation of MIG Verwaltungs AG in AFFIRIS GmbH represents the continuation of a tried-and-tested approach. Investment is only made in selected companies in Germany and Austria after their viability has been thoroughly audited. Their innovative, high-potential products and the entrepreneurial skills of their management teams are both key. MIG Verwaltungs AG is supported by Alfred Wieder AG. This specialist in venture capital is experienced in the sale of holdings and is therefore the first point of contact for any potential investors.
TURKS COULD GAIN MORE THAN ARMENIANS BY ACKNOWLEDGING THE GENOCIDE
By Harout Sassounian, Publisher, The California CourierHundreds of newspapers, internet sites, wire services, and radio and TV programs in Turkey, Azerbaijan, Armenia, Russia, France and many other countries had a field day with my column, "Armenians Demand ...OUTSTANDING RESULT FOR AFFIRIS ALZHEIMER'S VACCINE IN THE LATEST THOMSON "THE ONES TO WATCH" RANKING
Vienna, 19 December 2007. The Alzheimer's vaccine AD01 from AFFIRIS GmbH has been listed in first place in an analysis conducted by the international ranking agency Thomson Scientific into the prospects ...THE STATE OF MEDIA FREEDOM IN ARMENIA ACCORDING TO OSCE
OSCE Office for Democratic Institutions and Human Rights (ODIHR) published Needs Assessment Mission Report ahead of the 19 February 2008 Presidential Election in Armenia. The report also involves the ...SEFILIAN IN DEFENSE OF TER-PETROSIAN
Translated by L.H.Jirair Sefilian made a statement that says, "I am against the thinking that Levon is the president who wants to surrender Artsakh. It doesn't correspond to reality. Of course, we have serious contradictions ...SEMNEBY VISITED "ORINATS ERKIR" PARTY OFFICE
Translated by L.H.Arthur Baghdasarian met with EU Special Representative on South Caucasus Peter Semnebey in Orinats Erkir Party office. It is informed that issues of coming presidential elections were discussed. The ...GARZU IN NATIONAL GALLERY
By Melanya Badalian, translated by L.H.On December 20, in National Gallery opened an exhibition dedicated to well-known French Armenian artist Garzou. Garzou is one of the most famous Diaspora artists in Armenia. His 305 pictures are in our ...
WORLD'S MOST EXPENSIVE COUNTRIES
Translated by L.H.VAZGEN MANOUKIAN DEMANDING TO BE TREATED WITH RESPECT
Translated by L.H.TURKS COULD GAIN MORE THAN ARMENIANS BY ACKNOWLEDGING THE GENOCIDE
By Harout Sassounian, Publisher, The California Courier"YEREVAN CONTRIBUTES TO INTEGRATION OF TURKEY IN EU"
By Hakob Chakrian, translated by L.H.ARMENIAN MILITARY DOCTRINE
OUTSTANDING RESULT FOR AFFIRIS ALZHEIMER'S VACCINE IN THE LATEST THOMSON "THE ONES TO WATCH" RANKING
GARZU IN NATIONAL GALLERY
By Melanya Badalian, translated by L.H.TURKEY IS GUILTY OF ASSYRIANS AND GREEKS' GENOCIDE
Translated by L.H.NA SPEAKER NOT INDIFFERENT TO THE DEVELOPMENT OF CARPET MAKING IN ARMENIA
Translated by L.H.THE SWISS FEDERAL COURT CONDEMNS A DENIER OF THE ARMENIAN GENOCIDE
- 1904 Lenin publishes the first number of the "Vperyod" (Forward) newspaper in Geneva (Switzerland).
- 1931 Creation of the Radio Broadcasting Committee in Armenia.
- 1972 Death of Mkrtich Armen. He was born in 1906.
- 1986 The International Court of Justice decides on the Case Concerning the Frontier Dispute between Burkina Faso and Mali (554, 566-567). Certain aspects of this document may be significant in the resolution of the Artsakh crisis.
- 1993 The Azerbaijani army launches attacks along the length of its whole border with Artsakh. All attacks are repulsed with devastating losses for the aggressors. The aggression is abandoned in May 1994.
ARMENIAN NEWS
INTERACTIVE NEWS
INFORMATION
MY ARMTOWN
How to quit smoking?
How to write in Armenian on Windows XP?
All materials published on this website are taken from open sources and are copyrighted by their respective owners. You cannot reproduce or copy any materials published on armtown.com without written consent of original copyright holder. If you want to remove any material, please send us an email with proof of ownership/copyright and your material will be removed immediately. All materials published for information purposes only.